Long-form analysis on artificial intelligence, pharmaceutical R&D, clinical development, evidence, regulation and the future of work.
All insights
- From Evidence to Decisions: How AI Can Help Pharma Reach Better Development Decisions EarlierA practical framework for reducing evidence and decision latency in pharmaceutical R&D—and for using AI, MIDD and governance to reach better development decisions earlier.
- AI Will Not Eliminate CROs. It Will Redefine What Clients Pay Them ForAI is changing CRO economics, research-site requirements, patient matching and trial execution. See where new value will emerge in clinical R&D.
- AI Will Turn Pharma into an Evidence IndustryAI is making drug candidates abundant. See how evidence, pipeline governance, M&A, human data and portfolio decisions will reshape Pharma R&D.
- The Invisible Value of Experience: Why Companies Still Underestimate Professionals Over 50Experience drives judgment, resilience and performance. Discover why companies still undervalue professionals over 50—and what they lose by doing so.
- AI is moving faster than clinical trial regulation. The Pharma Market needs to talk about it.AI is advancing faster than clinical trial regulation. Explore the risks for Pharma, regulators, CROs and the future of evidence generation.
- The Pharma Market doesn’t have an AI problem. It probably has a process problem.Pharma may not have an AI problem, but a process problem. See why fragmented workflows, legacy systems and poor integration limit AI’s real impact.
- The next AI revolution in the Pharma Market won’t start only in the labPharma’s next AI transformation will extend beyond drug discovery. Explore how clinical development, operations, data and decision-making will change.
- The AI-Stigmatized Candidate: When Algorithms Decide Who Gets SeenAI screening can decide who gets seen—and who is excluded. Explore how hiring algorithms may reinforce bias, stigma and inequality in recruitment.